AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

868.941

-5.403-0.62%

Number of Gainers:10

Number of Losers:17

Number of Flat:19

PE:- -

High:875.874

Open:874.231

Low:865.875

Close:874.344

Loading ...

Immuron Ltd - Exclusive Distribution Agreement for Australia and New Zealand to Launch Proibs

THOMSON REUTERS

Race Oncology Ltd - Race Executes a$8.6M Contract to Support Phase 1 Trial of Rc220 in Solid Tumour Patients

THOMSON REUTERS

Australian shares decline, dragged by banks and miners, as Trump tariffs kick off

Invion raises $2M in share placement to support cancer research work

The Market Herald

Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal

MT Newswires Live

Wrong button: Biotron explains to ASX why possible bankruptcy wasn’t price sensitive

The Market Herald

BRIEF-Dimerix Receives Initial Upfront Payment From FUSO

BRIEF-Csl Ltd Says CSL Seqirus & Esperion Sign Licensing Agreement

CSL Ltd - CSL Seqirus & Esperion Sign Licensing Agreement to Commercialise Nexletol and Nexlizetin Australia & New Zealand

THOMSON REUTERS

BRIEF-Imugene Ltd Appoints Darren Keamy As CFO

Imricor Medical Systems Files Second Premarket Approval Module With US FDA; Shares Down 3%

MT Newswires Live

Invion Ltd-Proposed Issue of Securities - Ivx

THOMSON REUTERS

Dimerix posts modest gain as first Japanese payment for DMX-200 lands

The Market Herald

Imugene Appoints CFO; Shares Fall 3%

MT Newswires Live

Imugene Ltd - Appoints Darren Keamy as CFO and Company Secretary

THOMSON REUTERS

Imugene Ltd - Mike Tonroe Resigns as CFO

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":868.9408,"timestamp":1741137675186,"preClose":874.3437,"halted":0,"volume":52744820,"delay":0,"changeRate":-0.006179,"change":-5.402893,"amount":75203325,"amplitude":0.011436,"prevYearClose":936.801,"fiveDayClose":877.613,"twentyDayClose":903.442,"turnoverRate":0.001422,"marketCap":139615427162.5,"floatMarketCap":136158376149.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":875.8735,"amplitude":0.011436,"preClose":874.3437,"low":865.87463,"latestPrice":868.9408,"volume":52744820,"delay":0,"open":874.2309,"prevYearClose":936.801,"prevWeekClose":863.841,"prevMonthClose":863.841,"prevQuarterClose":936.801,"fiveDayClose":877.613,"twentyDayClose":903.442,"sixtyDayClose":934.137,"secType":"PLATE","market":"AU","turnoverRate":0.001422,"marketCap":139615427162.5,"floatMarketCap":136158376149.75,"timestamp":1741137675186,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":10,"down":17,"flat":19},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517998720","title":"Immuron Ltd - Exclusive Distribution Agreement for Australia and New Zealand to Launch Proibs","url":"https://stock-news.laohu8.com/highlight/detail?id=2517998720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517998720?lang=en_us&edition=fundamental","pubTime":"2025-03-05 06:51","pubTimestamp":1741128672,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2517984985","title":"Race Oncology Ltd - Race Executes a$8.6M Contract to Support Phase 1 Trial of Rc220 in Solid Tumour Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2517984985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517984985?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:58","pubTimestamp":1741125537,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN12W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","RAC.AU","BK7067"],"gpt_icon":0},{"id":"2516661278","title":"Australian shares decline, dragged by banks and miners, as Trump tariffs kick off","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661278?lang=en_us&edition=fundamental","pubTime":"2025-03-04 14:05","pubTimestamp":1741068324,"startTime":"0","endTime":"0","summary":"Australian shares decline, dragged by banks and miners, as Trump tariffs kick offUpdates to market closeAustralia's benchmark ASX200 slips 0.6% amid trade war fearsBanks fall 0.5%, miners fall 0.7%New Zealand benchmark falls 0.6%By Nikita Maria Jino","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN0D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7135","BK7067","BK7501","NAB.AU","BK7095","BK7046","BK7511","BK7507","BK7508","BHP.AU","MQG.AU","CSL.AU"],"gpt_icon":0},{"id":"2516642665","title":"Invion raises $2M in share placement to support cancer research work","url":"https://stock-news.laohu8.com/highlight/detail?id=2516642665","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516642665?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:46","pubTimestamp":1741059960,"startTime":"0","endTime":"0","summary":"Biotech company Invion Ltd  is raising $2 million in a two-tranche share placement to support a series of clinical trials and development activities for its Photosoft technology, seeking to treat a range of cancers.The company said it had completed the placement, with shares priced at 14 cents each – a 2.5% premium to the 30-day volume-weighted average price. This was chiefly managed by Blue Ocean Equities and has already attracted strong demand – reflected in the fact the initial goal was $1.5 million.The funds will go towards recruiting from a second site for the company’s Phase I/II skin cancer trial, and commencement of a Phase I/II anogenital trial in collaboration with the Peter MacCallum Cancer Centre in Melbourne.Crucially, a successful outcome in the latter could enable orphan drug designation in the U.S. to fast-track trials in the rare disease indications.The material provided in this article is for information only and should not be treated as investment advice. Viewers are","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/invion-raises-2m-in-share-placement-to-support-cancer-research-work-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","BK7509","IVX.AU","BK7096"],"gpt_icon":0},{"id":"2516136766","title":"Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516136766","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516136766?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:32","pubTimestamp":1741059169,"startTime":"0","endTime":"0","summary":"Dimerix  received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK7508","DXB.AU","BK7067","DMX","XAO.AU","XKO.AU","BK7501"],"gpt_icon":0},{"id":"2516613662","title":"Wrong button: Biotron explains to ASX why possible bankruptcy wasn’t price sensitive","url":"https://stock-news.laohu8.com/highlight/detail?id=2516613662","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516613662?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:23","pubTimestamp":1741058580,"startTime":"0","endTime":"0","summary":"Biotron  has been forced to explain its position to ASX Compliance after being queried by the regulator over why it didn’t classify as ‘price sensitive’ an announcement foreshadowing potential bankruptcy.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.Human error. Literally – the company ticked the wrong box.“The announcement was considered by the company to be market sensitive… Unfortunately, during lodgement of the announcement, the wrong box… was pressed. This was a human error,” Biotron wrote on Tuesday.As for additional concerns that the company didn’t make price sensitive a share purchase plan announcement, there too the regulator is worrying unduly – because Biotron made it clear it’s since changed that to a rights issue.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own res","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/wrong-button-biotron-explains-to-asx-why-possible-bankruptcy-wasnt-price-sensitive-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","BK7501","BK7508","BIT.AU"],"gpt_icon":0},{"id":"2516269987","title":"BRIEF-Dimerix Receives Initial Upfront Payment From FUSO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516269987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516269987?lang=en_us&edition=fundamental","pubTime":"2025-03-04 09:23","pubTimestamp":1741051414,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Receives Initial Upfront Payment From FUSOMarch 4  - Dimerix Ltd DXB.AX:RECEIVED UPFRONT PAYMENT OF 300 MILLION FROM FUSO PHARMACEUTICAL INDUSTRIESDIMERIX RECEIVES INITIAL UPFRONT PAYMENT FROM FUSOANTICIPATES A FURTHER 400 MILLION FROM FUSOFurther company coverage: DXB.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM0YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXB.AU","BK7067","BK7501","BK7508"],"gpt_icon":0},{"id":"2516696895","title":"BRIEF-Csl Ltd Says CSL Seqirus & Esperion Sign Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516696895","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516696895?lang=en_us&edition=fundamental","pubTime":"2025-03-04 09:01","pubTimestamp":1741050092,"startTime":"0","endTime":"0","summary":"BRIEF-Csl Ltd Says CSL Seqirus & Esperion Sign Licensing Agreement March 4 (Reuters) - CSL Ltd CSL.AX:CSL SEQIRUS & ESPERION SIGN LICENSING AGREEMENT TO COMMERCIALISE NEXLETOL AND NEXLIZET IN AUSTRALIA & NEW ZEALANDFurther company coverage: CSL.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM19B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7067","BK7511","CSL.AU"],"gpt_icon":0},{"id":"2516695406","title":"CSL Ltd - CSL Seqirus & Esperion Sign Licensing Agreement to Commercialise Nexletol and Nexlizetin Australia & New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2516695406","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516695406?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:54","pubTimestamp":1741049681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM19B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","CSL.AU","BK7511"],"gpt_icon":0},{"id":"2516693550","title":"BRIEF-Imugene Ltd Appoints Darren Keamy As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516693550","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516693550?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:25","pubTimestamp":1741047942,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Ltd Appoints Darren Keamy As CFO March 4 (Reuters) - Imugene Ltd IMU.AX:APPOINTS DARREN KEAMY AS CFO AND COMPANY SECRETARYMIKE TONROE RESIGNS AS CFOFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2516553693","title":"Imricor Medical Systems Files Second Premarket Approval Module With US FDA; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516553693","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516553693?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:24","pubTimestamp":1741047884,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems  submitted its second premarket approval module for US Food and Drug Administration  review, according to a Tuesday filing with the Australian bourse.The module covers design, manufacturing, and quality processes for seven products, and includes design controls, raw material receipt, inspection, storage, build procedures, process validation, part and device traceability, and quality management systems, the filing said.The company's NorthStar 3D mapping and guidance system will be submitted next under the 510 process.Shares fell nearly 3% in morning trade Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMR.AU","BK7503","BK7007","BK7508"],"gpt_icon":0},{"id":"2516494660","title":"Invion Ltd-Proposed Issue of Securities - Ivx","url":"https://stock-news.laohu8.com/highlight/detail?id=2516494660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516494660?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:49","pubTimestamp":1741045786,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUE9SJQN5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7509","BK7508","IVX.AU","BK7096"],"gpt_icon":0},{"id":"2516692168","title":"Dimerix posts modest gain as first Japanese payment for DMX-200 lands","url":"https://stock-news.laohu8.com/highlight/detail?id=2516692168","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516692168?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:46","pubTimestamp":1741045560,"startTime":"0","endTime":"0","summary":"Dimerix Ltd  has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries as part of a deal struck in January.Under that deal, FUSO and Dimerix teamed up to develop and commercialise Dimerix’s drug ‘DMX-200’ in Japan, which treats Focal Segmental Glomerulosclerosis , a scar tissue disease affecting kidneys.The $3.2M upfront payment is the first of multiple Dimerix expects, with up to $30M in payments possible under the FUSO deal. Another $4.1M is expected in the next six to 12 weeks as the first clinical trial in Japan begins.That timeframe is based on the certainty FUSO is already identifying trial sites ahead of the ‘ACTION3’ trial. Notably, FUSO is also responsible for all trial costs.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/dimerix-posts-modest-gain-as-first-japanese-payment-for-dmx-200-lands-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["FSGS","DXB.AU","BK7067","BK7501","DMX","BK7508"],"gpt_icon":0},{"id":"2516660815","title":"Imugene Appoints CFO; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516660815","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516660815?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:35","pubTimestamp":1741044931,"startTime":"0","endTime":"0","summary":"Imugene  appointed Clinuvel Pharmaceuticals'  former Chief Financial Officer Darren Keamy as CFO, effective immediately, according to a Tuesday filing with the Australian bourse.Keamy will succeed current CFO Mike Tonroe, the filing said.Shares of the pharmaceutical company fell 3% in recent trade,Price : $0.04, Change: $-0.00100, Percent Change: -2.78%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","CUV.AU","BK7067","IMU.AU","XKO.AU","BK7508","XAO.AU"],"gpt_icon":0},{"id":"2516661368","title":"Imugene Ltd - Appoints Darren Keamy as CFO and Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661368?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:01","pubTimestamp":1741039295,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMU.AU"],"gpt_icon":0},{"id":"2516661359","title":"Imugene Ltd - Mike Tonroe Resigns as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661359?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:01","pubTimestamp":1741039295,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM18W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMU.AU"],"gpt_icon":0}],"pageSize":16,"totalPage":9,"pageCount":1,"totalSize":138}]}}